science
Ipsen Agrees to Acquire Kartos Therapeutics
French drugmaker Ipsen will buy U.S.-based Kartos Therapeutics, which is developing a treatment for a rare blood cancer. The deal is Ipsen’s second acquisition this week.
zerohedge.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Ipsen agreed to acquire Kartos Therapeutics, a company developing a drug to treat a rare blood cancer. The transaction marks Ipsen’s second acquisition this week. @WSJ reported the agreement without disclosing financial terms or a closing timeline.
Kartos Therapeutics focuses on therapies for blood cancers with limited existing treatment options. The company’s lead program targets a specific mutation associated with certain myeloproliferative neoplasms. Ipsen has not commented on how the asset would fit into its existing oncology pipeline.
Transparency
How sources framed this
Single source — no framing comparison available.
CorroborationModerate · 1 source
